Halozyme Therapeutics, Inc
Price
FilingsNewest: 8-K, Director or officer changeSep 30 →InsidersNo open-market buys. 3 insiders sold $25.5M, 58 of 62 sales on a 10b5-1 plan.→HoldersBlackRock 11.6%Vanguard 4.7%Vanguard Portfolio 4.6%→PeersClosest companies: INCY, NKTR, VRTX→
From the filings
Figures
- Revenue
- $1.66Blast 12 months
- Net income
- $413.6Mlast 12 months
- Operating cash flow
- $677.4Mlast 12 months
- Cash and equivalents
- $163.1Mat the last balance sheet
- Total debt
- $2.15Bat the last balance sheet
- Shares outstanding
- 114.0M shareson issue